XML 54 R32.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Revenues (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Revenue from Contract with Customer [Abstract] |
Disaggregation of revenue by product and by geographic area | Revenues were as follows (in millions):
|  | Year ended December 31, 2021 |  | Year ended December 31, 2020 |  | Year ended December 31, 2019
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
Enbrel |  | $ | 4,352 |  |  | $ | 113 |  |  | $ | 4,465 |  |  | $ | 4,855 |  |  | $ | 141 |  |  | $ | 4,996 |  |  | $ | 5,050 |  |  | $ | 176 |  |  | $ | 5,226 |
Prolia |  | 2,150 |  |  | 1,098 |  |  | 3,248 |  |  | 1,830 |  |  | 933 |  |  | 2,763 |  |  | 1,772 |  |  | 900 |  |  | 2,672 |
Otezla(1) |  | 1,804 |  |  | 445 |  |  | 2,249 |  |  | 1,790 |  |  | 405 |  |  | 2,195 |  |  | 139 |  |  | 39 |  |  | 178 |
XGEVA |  | 1,434 |  |  | 584 |  |  | 2,018 |  |  | 1,405 |  |  | 494 |  |  | 1,899 |  |  | 1,457 |  |  | 478 |  |  | 1,935 |
Neulasta |  | 1,514 |  |  | 220 |  |  | 1,734 |  |  | 2,001 |  |  | 292 |  |  | 2,293 |  |  | 2,814 |  |  | 407 |  |  | 3,221 |
Aranesp |  | 537 |  |  | 943 |  |  | 1,480 |  |  | 629 |  |  | 939 |  |  | 1,568 |  |  | 758 |  |  | 971 |  |  | 1,729 |
Repatha |  | 557 |  |  | 560 |  |  | 1,117 |  |  | 459 |  |  | 428 |  |  | 887 |  |  | 376 |  |  | 285 |  |  | 661 |
KYPROLIS |  | 736 |  |  | 372 |  |  | 1,108 |  |  | 710 |  |  | 355 |  |  | 1,065 |  |  | 654 |  |  | 390 |  |  | 1,044 |
Nplate |  | 566 |  |  | 461 |  |  | 1,027 |  |  | 485 |  |  | 365 |  |  | 850 |  |  | 480 |  |  | 315 |  |  | 795 |
Other products |  | 3,636 |  |  | 2,215 |  |  | 5,851 |  |  | 3,821 |  |  | 1,903 |  |  | 5,724 |  |  | 3,031 |  |  | 1,712 |  |  | 4,743 |
Total product sales(2) |  | 17,286 |  |  | 7,011 |  |  | 24,297 |  |  | 17,985 |  |  | 6,255 |  |  | 24,240 |  |  | 16,531 |  |  | 5,673 |  |  | 22,204 |
Other revenues |  | 908 |  |  | 774 |  |  | 1,682 |  |  | 511 |  |  | 673 |  |  | 1,184 |  |  | 693 |  |  | 465 |  |  | 1,158 |
Total revenues |  | $ | 18,194 |  |  | $ | 7,785 |  |  | $ | 25,979 |  |  | $ | 18,496 |  |  | $ | 6,928 |  |  | $ | 25,424 |  |  | $ | 17,224 |  |  | $ | 6,138 |  |  | $ | 23,362 |
____________ (1) Otezla was acquired on November 21, 2019. (2) Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2021, 2020 and 2019.
Revenues earned from major customers | Certain information with respect to these customers was as follows (dollar amounts in millions):
| Years ended December 31,
| 2021 |  | 2020 |  | 2019
McKesson Corporation: |  |  |  |  |
Gross product sales | $ | 15,187 |  |  | $ | 13,779 |  |  | $ | 11,795 |
% of total gross revenues | 33 | % |  | 32 | % |  | 31 | %
AmerisourceBergen Corporation: |  |  |  |  |
Gross product sales | $ | 14,783 |  |  | $ | 14,743 |  |  | $ | 12,301 |
% of total gross revenues | 32 | % |  | 34 | % |  | 33 | %
Cardinal Health, Inc.: |  |  |  |  |
Gross product sales | $ | 7,681 |  |  | $ | 7,332 |  |  | $ | 6,538 |
% of total gross revenues | 17 | % |  | 17 | % |  | 17 | %

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration